NCT00371189 - Adenovirus Vaccine for Malaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Plasmodium Falciparum Infection

Interventions

DRUG

Placebo

Normal saline.

BIOLOGICAL

Ad35.CS.01 Circumsporozoite Malaria Vaccine

Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.

Trial Locations (2)

94305-2200

Stanford University School of Medicine, Stanford

37232-2573

Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH